Table 1. Pathway analysis of inflammatory (Dataset 2) and anti-inflammatory (Dataset 1) macrophage datasets.
| Dataset 2 | |||||||||||||
| Total Compounds | IFN list | LPS list | Interaction list | Entire list | |||||||||
| FDR | Impact | Hits | FDR | Impact | Hits | FDR | Impact | Hits | FDR | Impact | Hits | ||
| Pyrimidine metabolism | 12 | 0.003 | 0.021 | 2 | 0.002 | 0.021 | 2 | ||||||
| Butanoate metabolism | 5 | 0.005 | 0.029 | 1 | 0.000 | 0.029 | 2 | ||||||
| Citrate cycle (TCA cycle) | 8 | 0.002 | 0.068 | 1 | 0.002 | 0.068 | 1 | ||||||
| beta-Alanine metabolism | 4 | 0.003 | 0.444 | 1 | 0.002 | 0.444 | 1 | 0.002 | 0.444 | 1 | |||
| Glycerophospholipid metabolism | 7 | 0.005 | 0.044 | 1 | 0.003 | 0.068 | 2 | 0.004 | 0.068 | 2 | |||
| Glycine, serine and threonine metabolism | 7 | 0.007 | 0.031 | 2 | 0.019 | 0.031 | 2 | 0.011 | 0.031 | 3 | |||
| Purine metabolism | 15 | 0.000 | 0.127 | 2 | |||||||||
| Arginine and proline metabolism | 18 | 0.005 | 0.047 | 4 | 0.002 | 0.023 | 1 | 0.000 | 0.054 | 2 | 0.004 | 0.047 | 4 |
| Alanine, aspartate and glutamate metabolism | 13 | 0.005 | 0.114 | 1 | 0.002 | 0.063 | 1 | 0.001 | 0.022 | 1 | 0.000 | 0.177 | 2 |
| Taurine and hypotaurine metabolism | 4 | 0.001 | 0.714 | 2 | |||||||||
| Primary bile acid biosynthesis | 1 | 0.001 | 0.030 | 1 | |||||||||
| Dataset 1 | |||||||||||||
| Total Compounds | OIC list | LPS list | Interaction list | Entire list | |||||||||
| FDR | Impact | Hits | FDR | Impact | Hits | FDR | Impact | Hits | FDR | Impact | Hits | ||
| Glycerophospholipid metabolism | 6 | 0.010 | 0.044 | 1 | 0.010 | 0.044 | 1 | ||||||
| Glutathione metabolism | 8 | 0.010 | 0.003 | 1 | 0.011 | 0.003 | 1 | ||||||
| Histidine metabolism | 11 | 0.016 | 0.108 | 1 | 0.016 | 0.108 | 1 | ||||||
| Tyrosine metabolism | 5 | 0.021 | 0.001 | 1 | 0.021 | 0.001 | 1 | ||||||
| Glycine, serine and threonine metabolism | 10 | 0.002 | 0.031 | 1 | 0.002 | 0.031 | 1 | 0.003 | 0.031 | 2 | |||
| Arginine and proline metabolism | 20 | 0.002 | 0.023 | 1 | 0.006 | 0.012 | 2 | 0.002 | 0.023 | 1 | 0.003 | 0.035 | 3 |
| Citrate cycle (TCA cycle) | 9 | 0.002 | 0.068 | 1 | 0.003 | 0.068 | 1 | 0.002 | 0.068 | 1 | 0.003 | 0.068 | 1 |
| Alanine, aspartate and glutamate metabolism | 12 | 0.002 | 0.063 | 1 | 0.003 | 0.063 | 1 | 0.002 | 0.063 | 1 | 0.003 | 0.063 | 1 |
| Pyrimidine metabolism | 20 | 0.002 | 0.140 | 5 | 0.003 | 0.147 | 6 | 0.002 | 0.133 | 4 | 0.003 | 0.147 | 6 |
| beta-Alanine metabolism | 5 | 0.002 | 0.444 | 1 | 0.003 | 0.444 | 1 | 0.002 | 0.444 | 1 | 0.003 | 0.444 | 1 |
| Purine metabolism | 21 | 0.009 | 0.005 | 1 | 0.011 | 0.005 | 1 | ||||||
| Phenylalanine metabolism | 5 | 0.018 | 0.130 | 1 | 0.017 | 0.130 | 1 | 0.018 | 0.130 | 1 | |||
Analysis was conducted on log-transformed data (Kegg IDS) using MetaboAnalyst. Here the GlobalTest was used in conjunction with the Relative-betweeness Centrality algorithm. For each dataset, a list of all detected metabolites (Kegg IDs) was used as a background. Dataset 1 refers to the anti-inflammatory dataset and Dataset 2 refers to the inflammatory dataset. The maximum importance of each pathway is 1, and the pathway impact is the cumulative proportion from the matched metabolite nodes.